Skip to main content

Prometheus Biosciences Inc (RXDX) Stock Forecast 2025 - AI Price Prediction & Analysis


Prometheus Biosciences Inc (RXDX) AI Stock Price Forecast & Investment Analysis

Prometheus Biosciences Inc Stock Price Chart and Technical Analysis

Loading Prometheus Biosciences Inc interactive price chart and technical analysis...

Prometheus Biosciences Inc (RXDX) - Comprehensive Stock Analysis & Investment Research

Deep dive into Prometheus Biosciences Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Prometheus Biosciences Inc, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Prometheus Biosciences Inc: Prometheus Biosciences Inc operates in the Manufacturing sector, establishing it as a mid-cap growth opportunity.

Prometheus Biosciences Inc (Stock Symbol: RXDX) is a leading company in the Manufacturing sector , specifically operating within the Pharmaceutical Preparation Manufacturing industry.

The organization employs approximately 72 professionals worldwide and operates under the strategic leadership of CEO Mark C. McKenna.

The company has established itself as a growing mid-cap opportunity with strong fundamentals.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Prometheus Biosciences Inc's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Prometheus Biosciences Inc: With $125M in annual revenue and -87.9% net margin, the company demonstrates developing profitability.

Annual Revenue: $125 million generating a -87.9% net profit margin .

Market Capitalization: $9539 million - Classified as a mid-cap growth stock with balanced risk-reward profile.

Return on Equity (ROE): -42.7% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Prometheus Biosciences Inc stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Prometheus Biosciences Inc: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Prometheus Biosciences Inc stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Prometheus Biosciences Inc's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Prometheus Biosciences Inc: Market positioning analysis based on available financial and operational metrics.

Prometheus Biosciences Inc strategically competes in the highly dynamic Pharmaceutical Preparation Manufacturing marketplace, establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share .

The company maintains a healthy 3.2% gross margin, indicating strong pricing power and operational efficiency.

Prometheus Biosciences Inc (RXDX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Prometheus Biosciences Inc stock analysis.

Loading Prometheus Biosciences Inc comprehensive fundamental analysis and insider trading data...

Deep dive into Prometheus Biosciences Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Prometheus Biosciences Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Prometheus Biosciences Inc: With a P/E ratio of -66.39, the market sees the stock as potentially undervalued.

P/E Ratio -66.39x
P/B Ratio 13.67x
Market Cap $9539M
EPS $-1.78
Book Value/Share $14.62
Revenue/Share $0.08
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Prometheus Biosciences Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Prometheus Biosciences Inc: An ROE of -42.7% indicates room for improvement in shareholder value creation.

ROE -42.7%
ROA -37.8%
ROIC -40.9%
Gross Margin 3.2%
Operating Margin -129.6%
Net Margin -87.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Prometheus Biosciences Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Prometheus Biosciences Inc: A current ratio of 13.56 indicates strong liquidity.

Current Ratio 13.56x
Quick Ratio 13.18x
D/E Ratio 0.07x
Financial Leverage 1.23x
Interest Coverage -532.6x
Working Capital $42M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Prometheus Biosciences Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Prometheus Biosciences Inc: Free cash flow of $-76M indicates cash challenges that need attention.

Operating Cash Flow $-74M
Free Cash Flow $-76M
Capital Spending $-2M
CapEx/Sales 28.5%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Prometheus Biosciences Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Prometheus Biosciences Inc: An asset turnover of 0.02x suggests room for improvement in asset utilization.

Asset Turnover 0.02x
Receivables Turnover 5.6x
Fixed Assets Turnover 0.7x
Days Sales Outstanding 66 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Prometheus Biosciences Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Prometheus Biosciences Inc: With annual revenue of $125M, Prometheus Biosciences Inc demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $125M
Operating Income $-162M
Net Income $-110M
R&D Expense $121M
SG&A Expense $499M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 93%
Cash & Short-term Investments 90%
Total Liabilities 18%
Short-term Debt 2%
Accounts Receivable 1%
Dividend & Shareholder Information
Shares Outstanding 48M
Growth Metrics (YoY)
EPS Growth -0.9%

Latest Prometheus Biosciences Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Prometheus Biosciences Inc (RXDX) stock price and investment outlook.

Prometheus Biosciences Inc Competitors & Peer Analysis - Manufacturing Sector

Comparative analysis of Prometheus Biosciences Inc against industry peers and competitors in the Manufacturing sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Prometheus Biosciences Inc Stock Forecast

How accurate are Prometheus Biosciences Inc stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for RXDX predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Prometheus Biosciences Inc stock price forecasts?

Our analysis considers Prometheus Biosciences Inc's financial metrics, Manufacturing sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Prometheus Biosciences Inc a good investment in 2025?

Based on our AI analysis, Prometheus Biosciences Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Prometheus Biosciences Inc forecasts updated?

Prometheus Biosciences Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Prometheus Biosciences Inc Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Prometheus Biosciences Inc stock.

My Portfolio

Investment Dashboard

Loading your portfolio...